Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369462 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2020.05.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Refractory benign familial pemphigus successfully treated with dupilumab: a case series.
Clin Exp Dermatol
December 2024
Dermatology Department, Hospital Universitario Infanta Leonor, Madrid, Spain.
Benign familial pemphigus (BFP) is a chronic autosomal dominant dermatosis characterized by the appearance of flaccid blisters which evolve to painful erythematous macerated plaques and erosions in intertriginous areas. While different medical therapies for BFP exist, current treatments are not consistently effective, and symptoms often cause decreased quality of life. We report a case series of three patients with refractory moderate-to severe BFP which have been successfully treated with dupilumab, describing clinical evolution within a follow-up period of 18 months.
View Article and Find Full Text PDFMechanisms of Resistance to Rituximab Used for the Treatment of Autoimmune Blistering Diseases.
Life (Basel)
September 2024
Department of Dermatology, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street, District 1, 020021 Bucharest, Romania.
Autoimmune blistering diseases represent a group of chronic severe, disabling, and potentially fatal disorders of the skin and/or mucous membranes, primarily mediated by pathogenic auto-antibodies. Despite their rarity, these diseases are associated with significant morbidity and mortality and profound negative impact on the patient's quality of life and impose a considerable economic burden. Rituximab, an anti-CD-20 monoclonal antibody, represents the first line of therapy for pemphigus, regardless of severity and a valuable off-label therapeutic alternative for subepidermal autoimmune blistering diseases as it ensures high rates of rapid, long-lasting complete remission.
View Article and Find Full Text PDFAcalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial.
Ann Hematol
September 2024
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Acalabrutinib is a highly selective Bruton tyrosine kinase inhibitor approved in the United States and Europe for chronic lymphocytic leukemia (CLL) based on phase 3 trials with limited representation of Asian populations. This phase 1/2 trial evaluates acalabrutinib in Chinese adults with relapsed/refractory (R/R) CLL receiving acalabrutinib 100 mg twice daily in 28-day cycles until disease progression or treatment discontinuation due to adverse events (AEs) presenting substantial clinical risk. The primary endpoint was blinded independent central review (BICR)-assessed overall response rate (ORR).
View Article and Find Full Text PDFUpadacitinib leading to resolution of refractory mucosal erosions in a case of pemphigus vulgaris.
Int J Dermatol
August 2024
Icahn School of Medicine, Mount Sinai, New York, NY, USA.
A Case of Refractory Pemphigus Herpetiformis with Positive Anti-Desmoglein 1 Antibody: Case Report and Literature Review to Revisit the Disease Characteristics of 167 Cases.
Indian J Dermatol
June 2024
From the Department of Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!